Advanced Renal Cell Carcinoma
Advertisement
Machine learning may be a useful tool in predicting renal cell carcinoma tumor response to nivolumab monotherapy.
Patients with mRCC and primary resistant disease to nivolumab plus ipilimumab have worse survival outcomes.
Drs. Beckermann and Braun reflect on key lessons from the trial, emphasizing the importance of prioritizing driver mutations.
Drs. Beckermann and Braun break down the selection process for neoantigens in the trial for personalized RCC vaccines.
Drs. Beckermann and Braun discuss the latter's Nature publication on a personalized neoantigen vaccine for RCC.
Patients with mRCC on Medicare have better survival rates compared with patients on Medicaid or with no insurance.
The combination therapy provided similar survival rates and toxicity in an older patient population.
Dr. Daniel Joyce gives an overview of his study that examined the use of necrosis as a prognostic indicator for mRCC.
First-line IO + IO therapy is linked to higher costs during the first three months of treatment.
Patients were administered oral belzutifan, 120 mg once daily, in addition to oral cabozantinib, 60 mg once daily.
Dr. Albiges discusses the logistical benefits and considerations of subcutaneous administration of nivolumab for RCC.
Dr. Albiges summarizes the CheckMate 67T study, which evaluated the safety and efficacy of subcutaneous nivolumab for RCC.
Dr. Barragán-Carrillo discusses the current state of RCC treatment, including ICIs, TKIs, and dual ICI regimens.
The panelists discuss promising new advancements and novel therapies for treating RCC, including LAG-3 and CAR-T therapies.
The panel discusses how designing effective trials could refine the approach to treatment strategies for RCC.
Part 3 of this roundtable examines adjuvant pembrolizumab and the role of TKIs in treatment sequencing for RCC.
The panelists examine the data on TKIs and immunotherapy for RCC from the TiNivo-2 trial.
Part 1 of this roundtable examines the key differences between the CONTACT-03 and TiNivo-2 trials.
Drs. Beckermann and Barata explore the implications of the negative findings of the CONTACT-03 trial on clinical practice.
In the final part of this roundtable series, the panelists share their thoughts on the most anticipated upcoming trials.
630 Madison Ave.
Manalapan, NJ 07726
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.